BiotechTube
HealthBio AI

HealthBio AI

Boston, United States· Est.
healthbioai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

HealthBio AI is a clinical-stage biotech company developing an integrated platform of AI-driven diagnostics and therapeutics for chronic inflammatory diseases. The company's core hypothesis centers on immune dysregulation driven by persistent viral proteins, such as the SARS-CoV-2 S1 protein in Long COVID. With an FDA-accepted Phase 2/3 clinical trial for a Long COVID therapeutic and a commercial diagnostic test, HealthBio AI is pursuing a vertically integrated model from diagnosis to treatment management. The company is privately held and appears to be in an early-revenue stage, supported by diagnostic test sales.

Long COVIDChronic Inflammatory DiseasesME/CFSChronic Lyme DiseaseFibromyalgia

Technology Platform

AI and machine learning platform that analyzes health data to identify molecular root causes of chronic inflammatory diseases. It integrates biomarker discovery (e.g., persistent S1 protein in monocytes) with predictive modeling to develop diagnostics and therapeutics.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The massive, underserved patient populations in Long COVID (22M in US), ME/CFS, fibromyalgia, and related conditions represent a multi-billion dollar market with no approved targeted therapies.
Success in Long COVID provides a validated platform to rapidly expand into other chronic inflammatory and autoimmune diseases, including oncology and Alzheimer's.

Risk Factors

High risk of clinical trial failure for its novel therapeutic hypothesis.
Future commercial success depends on regulatory approval, payer reimbursement, and market adoption against potential competitors.
As a private company, it faces significant financing risk to fund expensive late-stage clinical development.

Competitive Landscape

The Long COVID and chronic inflammatory disease space is becoming increasingly competitive, with numerous biopharma companies, academic centers, and diagnostics firms exploring mechanisms and interventions. HealthBio AI's differentiation lies in its integrated AI-to-therapeutics platform and specific focus on the S1 protein/CCR5 axis, but it must compete for clinical validation, patient recruitment, and market share.

More companies in AI / Machine Learning →More companies in United States →